Business Wire

Ferring Announces Positive Outcome of European Decentralised Procedure (DCP) for Testavan®, a Treatment for Men with Hypogonadism

Jaa

Ferring Pharmaceuticals today announced the positive outcome of the European Decentralised Procedure (DCP) for Testavan® (transdermal testosterone gel 2%), a testosterone replacement therapy for adult male hypogonadism, when testosterone deficiency has been confirmed by clinical features and biochemical tests. The Netherlands acted as Reference Member State (RMS) on behalf of all 31 European Economic Areas (EEA) countries.1

Men suffering from hypogonadism symptoms, including erectile dysfunction and fatigue, often remain untreated due to barriers that delay diagnosis and lack of treatment options,” said Per Falk, Executive Vice President and Chief Science Officer, Ferring Pharmaceuticals. “Ferring is committed to delivering innovative healthcare solutions to treat a number of male urologic conditions. With the positive outcome of the DCP, hypogonadal patients in many European countries will soon have access to a convenient treatment to normalise testosterone and relieve symptoms.

Testavan’s fast-drying gel formulation is based on Ferring’s Advanced Skin Technology (F.A.S.T.), a proprietary transdermal gel technology, which enhances bioavailability of testosterone through the skin. Testavan’s low dose and volume, in addition to its unique hands-free applicator, were designed to ensure patient convenience. The hands-free applicator may lower the risk of transference of testosterone skin residue from the patient to others.8-10

In phase III trials, men treated with Testavan achieved normalised testosterone levels by month three, with improvements in quality of life and fatigue scores over three months, and early and sustained increase in erectile function score at one and three months. Assessment measures included testosterone responder rate, defined as the percentage of subjects achieving normalised levels of testosterone (300-1050 ng/dL); the Multidimensional Assessment of Fatigue (MAF); general well-being assessment (Short Form 12 Health Survey, SF-12); International Index of Erectile Function (IIEF).

About male hypogonadism

Male hypogonadism is a condition characterised by low levels or absence of testosterone due to certain medical conditions, and signs and symptoms of testosterone deficiency. Male hypogonadism is reported to have an incidence of 2-6% in men aged 40-79 years and becomes more common with age.3 There is a substantial quality of life and clinical burden associated with hypogonadism in men, and can be associated with comorbidities such as diabetes, metabolic syndrome, cardiovascular diseases, and adverse bonehealth.3,11-14

About Testavan

Testavan, the new 2% testosterone gel, uses a proprietary hydroalcoholic and highly viscous topical formulation. The product is homogeneous, transparent and nonstaining, and comes in a metered dose dispenser that includes a hands-free cap applicator for precise dispensing and application. The starting dose is 23 mg testosterone, delivered by one pump actuation, contained in 1.15 g of gel, and the highest dose is 3.45 g of gel containing 69 mg testosterone (delivered by 3 pump actuations).1

About Ferring Pharmaceuticals

Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and women’s health, and in specialty areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years. Today, over one third of the company’s research and development investment goes towards finding innovative and personalised healthcare solutions to help mothers and babies, from conception to birth. Founded in 1950, Ferring now employs approximately 6,500 people worldwide, has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries.

Learn more at www.ferring.com and @Ferring, or connect with us on Facebook, Instagram and LinkedIn.

# # #

References

1 Ferring Pharmaceuticals. Data on file 2018.
2 Nieschlag E, Behre HM (eds). Andrology: male reproductive health and dysfunction. 3rd edn. Heidelberg: Springer, 2010.
3 Dohle G. et al. Guidelines on Male Hypogonadism. EAU guidelines 2017. Available at: http://uroweb.org/guideline/male-hypogonadism/#note_4 Last accessed: March 2018
4 Belkoff L. et al. Efficacy and safety of testosterone replacement gel for treating hypogonadism in men: Phase III open label studies. Andrologia 2018 Feb;50(1). doi: 10.1111/and.12801. Epub 2017 Mar 10.
5 Arver S. et al. A new 2% testosterone gel formulation: A comparison with currently available topical preparations. In Press. Andrology 2018.
6 Cunningham G et al. Efficacy and safety of a new topical testosterone replacement gel therapy for the treatment of male hypogonadism. Endocr Pract 2017;23(5):557-565.
7 Testavan Summary of Product Characteristics. Ferring Pharmaceuticals.
8 Alberti I. et al. Pharmaceutical development and clinical effectiveness of a novel gel technology for transdermal drug delivery. Expert Opin Drug Deliv 2005;2:935-950.
9 Olsson H. et al. Pharmacokinetics and Bioavailability of a New Testosterone Gel Formulation in Comparison to Testogel in Healthy Men. Clin Pharmacol Drug Dev 2014;3(5):358-64.
10 Efros M., Carrara D., Neijber A. The efficacy, bioavailability and safety of a novel hydroalcoholic testosterone gel 2% in hypogonadal men: results from phase II open-label studies. Andrologia 2016;48(6):637-645.
11 Kalyani RR, Dobs AS. Androgen deficiency, diabetes, and the metabolic syndrome in men. Curr Opin Endocrinol Diabetes Obes 2007;14(3):226-234.
12 García-Cruz E. et al. Metabolic syndrome in men with low testosterone levels: relationship with cardiovascular risk factors and comorbidities and with erectile dysfunction. J Sex Med 2013;10(10);2529-2538.
13 Rodriguez-Tolrà J. et al. Effects of testosterone treatment on bone mineral density in men with testosterone deficiency syndrome. Andrology 2013;1(4):570-575.
14 Zarotsky V. et al. Systematic literature review of the risk factors, comorbidities, and consequences of hypogonadism in men. Andrology 2014;2(6):819-834.

Contact information

Ferring Pharmaceuticals
Bhavin Vaid
Head of Corporate Communications
+41 583010952 (direct)
+41 791910632 (mobile)
bhavin.vaid@ferring.com
Lindsey Rodger
Senior Manager, Corporate Communications
+41 584514023 (direct)
+41 791910486 (mobile)
lindsey.rodger@ferring.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Nexperia Secures $800M Financing to Fund Future Growth Plans19.4.2018 12:33Tiedote

Nexperia, the global leader in discretes, logic and MOSFET devices, today announced the successful completion of a refinancing of its current facilities with USD 800 million equivalent of senior credit facilities. This includes a significant proportion of Revolving Credit facility. The proceeds will be used to refinance existing outstanding debt and for Capex expenditure to fund future growth. The facilities were arranged by Bank of America Merrill Lynch and HSBC, acting as Global Coordinators, and were syndicated by a group of nine global banks. The refinancing is fully supported by JAC Capital and Wise Road Capital, Nexperia’s two main shareholders, and provides a flexible financing package at very attractive terms to support the further growth of Nexperia going forward. Comments from Frans Scheper, Nexperia’s CEO: “This is the first time that Nexperia has approached the financial markets as an independent company, so we are very pleased with the enthusiastic response. Refinancing th

Grundig – Redefining Kitchen Design and Technology19.4.2018 12:19Tiedote

UNLEASH YOUR GOURMET CAPABILITIES WITH GRUNDIG’S GOURMET CHEF™ OVEN This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180419005580/en/ (Photo: Grundig) Grundig’s Gourmet Chef™ Oven makes cooking elaborate, delicious meals easier than ever before. The oven’s intuitive design and innovative technology combine to simplify cooking and cleaning processes, inspire culinary creativity, and produce exquisite results. Equipped with advanced connected technologies and sensors, it allows users to precisely control the temperature of their food as it cooks to ensure the best results. This includes a high temperature moisture sensor, a temperature control sensor and BLDC motor, an integrated camera and a multipoint meat probe. Cleaning up after your culinary creation couldn’t be easier for users, with the oven fitted with advanced automatic self cleaning, including water and high-pressure steam cleaning, The Gourmet Chef™ elegant and sophis

PIXID Continues European Expansion with Acquisition of Dutch Staffing CRM Supplier Carerix19.4.2018 12:09Tiedote

European workforce management solutions provider PIXID, has acquired Carerix, a Dutch-based CRM and ATS supplier, to further strengthen its proposition and expand its operations. Adding a leading supplier for CRM and ATS systems to its ranks allows PIXID to reinforce its expertise, enhance its service offering and strengthen the value chain offered to the temporary employment sector. The purchase also means PIXID can now add a presence in Benelux to its existing offices in France, in the UK (since its acquisition of The Internet Corporation in 2017) and its operations in Germany. A complete online software solution for recruitment and staffing agencies, Carerix is currently helping more than 10,000 users every day. It has a presence in 17 countries due to high-profile relationships with major customers including Randstad, Adecco, Manpower, T-Groep and DPA. Carerix has a multi-level partnership programme and an ecosystem which allows for a tailored offering and broader promotion of its

I4MS Will Boost Industry 4.0 Opportunities at Hannover Messe19.4.2018 12:00Tiedote

I4MS will be part of the European Commission’s space in Hannover Messe. Together with Fortissimo Project, I4MS, the European Initiative created to foster digitisation for Manufacturing SMEs in Europe, will be presenting their last experiments that demonstrated new technology solutions for SMEs in manufacturing and related segments. The exhibition is designed to feature the European Commission’s strong aim of helping SMEs to digitise their business, and to promote the current mix of European-scale activities in place through European initiatives like I4MS and Smart Anything Everywhere (SAE), and also specific projects like Fortissimo. To showcase this commitment, the stand will receive institutional visits, such as Mrs. Elzbieta Bienkowska, European Commissioner for Internal Market, Industry, Entrepreneurship and SMEs and Mr. Reinhard Bütikofer, Member of the European Parliament. Visitors to the European Commission’s (Hall 6 stand G46) stand will see different innovative experiment’s de

Sigma Systems Selected for Stratecast’s Global ODAM ‘Ten to Watch’19.4.2018 12:00Tiedote

Sigma Systems, the global leader in catalog-driven software, has been chosen as one of the Stratecast | Frost & Sullivan Operations, Orchestration, Data Analytics & Monetization (ODAM) Ten to Watch in 2018. Stratecast produces an annual Global Ten to Watch report to highlight organizations that are making a difference in their respective disciplines when it comes to upgraded capabilities for meeting the demands of business and technological change. As noted in the report, Sigma has made the watchlist because of its business momentum combined with its innovative solutions to help service providers transform. The report recognizes that Sigma enjoyed one of its best years commercially in 2017 as it added new customers like Inmarsat and a major mobile operator in Asia among others, and is looking for a repeat in 2018. Sigma is continuing to develop and offer innovative solutions (including the recently released Sigma Insights) that address critical business objectives and challenges faced

Grundig Announces Massimo Bottura as Inaugural Brand Ambassador19.4.2018 12:00Tiedote

Grundig, Europe’s leading full range manufacturer of home electronics, is pleased to announce Michelin star chef and gastronomic leader, Massimo Bottura, as its inaugural brand ambassador. In his new role as Grundig’s official brand ambassador, Bottura will be working closely with the company to further their shared vision around quality, innovation and culture - helping make homes and the world a better place. The chef and patron of Osteria Francescana, who is recognised as one of the world’s most influential creative geniuses by The New York Times, will be putting his knowledge of food and the arts to use, collaborating with Grundig to design a range of home and consumer appliances. Taking influence from his passion for music and art, the bespoke products will be launched later in the year and will utilise the latest in technology and innovation, coupled with the refined design Grundig is known for. The ambassadorship was announced at Grundig’s Respect Food event supporting the cultu

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme